Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])

NCT06951217 is registered in ClinicalTrials.gov with Avalyn Pharma Inc. as lead sponsor.

NCT NCT06951217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06951217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])
Lead sponsor
Avalyn Pharma Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 17, 2025
Completion date
December 31, 2031
Enrollment
340 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis (ipf), progressive pulmonary fibrosis